000			01245nam a2200133Ia 4500
008			220620s9999||||xx |||||||||||||| ||und||
020			_a9783040000000
245		4	_aThe Role of Complement in Cancer Immunotherapy
546			_aEnglish[eng]
650			_acomplement||therapeutic monoclonal antibodies (mAbs)||Ca2+||fluorescence microscopy||gC1qR||breast cancer||xenotransplant model||complement system||cancer||immune infiltrate||tumor microenvironment||tumor growth||anaphylatoxins||antibody dependent cellular cytotoxicity||phagocytosis||complement receptors||CD46||membrane cofactor protein (MCP)||cancer therapeutics||measles virus||adenovirus||antibody-drug conjugates||immunity||myeloid cells||therapeutics||antibody therapy||cluster of differentiation 19 (CD19)||CD19||Fc fragment crystallizable (Fc)||Fc engineering||complement-dependent cytotoxicity (CDC)||antibody-dependent cell-mediated cytotoxicity (ADCC)||angiogenesis||ocular pathology||cytotoxicity||monoclonal antibody||B-cell lymphoma||chronic lymphocytic leukemia (CLL)||complement C5a||complement C3a||mammary carcinoma||immunoregulation||tumor infiltrating leukocytes||n/a
700			_aTaylor, Ronald P.
856			_uhttps://mdpi.com/books/pdfview/book/4923
942			_cEB
999			_c32361 _d32361